CYPHERPUNK TECHNOLOGIES INC, a company operating within the Health Care sector and specifically within the Biotechnology industry, has been a subject of interest in recent financial analyses. Listed on the Nasdaq stock exchange, the company’s financial metrics and market performance provide a comprehensive view of its current standing.
As of September 28, 2026, CYPHERPUNK TECHNOLOGIES INC’s close price was recorded at $3.23. This figure is significant when compared to its 52-week high of $4.19, achieved on September 24, 2026, and its 52-week low of $0.393, which occurred on November 5, 2025. These fluctuations highlight the volatility experienced by the company within the past year.
The market capitalization of CYPHERPUNK TECHNOLOGIES INC stands at $356.7 million USD, reflecting its valuation in the current market. However, the company’s Price Earnings (P/E) ratio is notably negative at -512.88. This negative P/E ratio indicates that the company is currently not generating profits, which is a critical factor for investors to consider.
CYPHERPUNK TECHNOLOGIES INC’s operations are primarily focused on the development of novel therapeutics for the treatment of cancer. As a clinical-stage biopharmaceutical company, it is engaged in cutting-edge research and development activities aimed at addressing unmet medical needs in oncology. The company’s global reach allows it to serve customers worldwide, positioning it as a significant player in the biotechnology sector.
For further information on CYPHERPUNK TECHNOLOGIES INC’s activities, offerings, and financial performance, stakeholders are encouraged to visit their official website. Additionally, as a publicly traded entity on the Nasdaq, the company’s financial disclosures and updates are regularly made available to the public, ensuring transparency and accessibility for investors and interested parties.
